Chair, through you, as I stated previously, the medical efficacy and the public health impacts of safe supply and harm reduction strategies are, for me, best left with medical professionals and public health experts.
My concern, in my role in the safe supply diversion, involves just what we spoke about. One issue is that individuals in the program—